Exposure over time: peptide pharmacokinetics and half-life

The administered amount is only one part of drug exposure. Absorption, distribution, elimination, and repeated administration determine how concentrations change over time.

Absorption and bioavailability

Absorption describes the passage of a drug from the administration site into the bloodstream. Bioavailability expresses the fraction of a dose that reaches the systemic circulation unchanged. By definition, intravenous administration provides complete bioavailability. Other routes depend on barriers and formulation characteristics. For many peptides, digestive enzymes and intestinal permeability limit oral exposure. However, formulations exist that are designed to overcome some of these barriers. The conclusion should always refer to the specific product being studied. Knowing the name of the active ingredient is insufficient. Route, formulation, and conditions of administration can change the amount that ultimately reaches the body and its variability.

Distribution

After reaching the bloodstream, the drug can distribute between plasma and tissues. The volume of distribution relates the amount present in the body to its plasma concentration. It is an apparent volume, not an anatomical cavity that we can directly measure. Protein binding and tissue affinity influence this relationship. In modified peptides, these properties can be incorporated into drug design. However, a plasma concentration does not fully describe the exposure of all tissues. We must avoid interpreting a large volume as a literal measure of body size. The parameter summarizes a behavior, and its usefulness depends on the model used.

Clearance

Clearance expresses the body's ability to eliminate a drug in relation to its concentration. It is represented as a volume per unit of time. It should not be confused with the absolute amount eliminated in that period. Peptides can undergo proteolytic degradation and other processes depending on their characteristics. The relative contributions of renal and hepatic processes differ among peptides and may also vary between patients. Therefore, an alteration in one organ does not allow us to predict the same adjustment for every molecule. We need product studies and specific recommendations. On a curve, a change in clearance can modify exposure and persistence. Identifying this possibility helps interpret differences between individuals without automatically attributing them to receptor variation.

Half-life

Half-life is the time required for a concentration to decrease by half in a defined phase. In a simple first-order model, it depends on the volume of distribution and clearance. This relationship assumes conditions that must be reviewed before applying it. Some profiles have several phases, and a terminal half-life does not summarize the entire initial behavior. Furthermore, the duration of effect may differ from plasma persistence. A biological signal may continue after a change in concentration. When reading a half-life figure, ask which phase it describes and how it was estimated. Half-life provides guidance but does not, on its own, determine the optimal administration frequency.

Accumulation and steady state

If a new dose is administered before the previous one is completely eliminated, accumulation can occur. With a fixed repeated dosing regimen and stable pharmacokinetics that permit a finite steady state, the amount of drug reaching the systemic circulation over each dosing interval approaches the amount eliminated. Concentrations may still rise and fall within each interval. This steady state does not require a flat concentration. A steady state does not mean that its concentrations are safe or therapeutic. In first-order models, this equilibrium is usually approximated after several half-lives. The word "approximated" is important because equilibrium is reached gradually. Changing the dose can modify the level of exposure without necessarily accelerating this process. In clinical practice, these principles help explain why an overly early assessment can be misleading. Specific time points must be confirmed for the formulation and regimen being studied.

Exposure and peak concentration

The area under the curve summarizes the cumulative exposure over a given interval. The maximum concentration describes the observed peak. The time to that peak indicates the speed of the exposure profile, although it depends on several processes. Two formulations may have similar areas under the curve but different peaks. This does not prove that they are interchangeable or that they produce identical tolerability. We need to know what comparisons were made and what criteria were used. When reviewing a study, first identify the integration interval and the administration conditions. Also, review the inter-person variability. An average exposure may mask important differences. Clinical interpretation requires linking the exposure profile to documented response and safety data.

A formulation-specific example

Semaglutide illustrates how molecular design modifies a peptide's exposure. Its characteristics promote resistance to degradation and albumin binding. The formulation adds another layer of pharmacokinetic behavior. In studies of the oral formulation, the administration conditions influenced exposure. This example does not allow for the transfer of instructions across all available formulations. Nor does it convert a tablet and an injection into equivalent quantities by simply comparing mass. Interpretation must consider the specific product, route of administration, and study. When a consultation mixes these variables, it is advisable to explicitly separate them. This prevents attributing to the molecule a change that actually stems from the formulation used.

What to remember

Half-life describes a time course under specified conditions. It does not supply a universal schedule, establish equivalence between routes, or replace product-specific clinical evidence.

Continue with PEPTIDE Academy, Module 2. The complete lessons remain in the Academy; this public article introduces selected concepts.